ImmunoGen Stock Price - IMGN

6.72
-0.08 (-1.18%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
ImmunoGen Inc IMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
1.44 26.87% 6.80 5.88 7.07 6.00 5.36 23:59:43
Bid Price Ask Price Spread Spread % News
6.72 6.79 0.07 1.03% 4 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
78,530 24,030,418 $ 6.55 $ 157,486,973 3,422,774 1.65 - 7.07
Last Trade Time Type Quantity Stock Price Currency
19:54:04 28 $ 6.72 USD

ImmunoGen Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.18B 174.22M $ -168.84M -1.22 - 171.91M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 4.00 1.50%

more financials information »

ImmunoGen News

Loading Messages....

Latest IMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.807.074.505.032,164,0192.0041.67%
1 Month4.887.074.204.832,774,0911.9239.34%
3 Months3.257.073.254.653,009,9553.55109.23%
6 Months2.847.072.2253.972,177,0973.96139.44%
1 Year5.457.071.653.172,704,5471.3524.77%
3 Years2.3513.411.655.942,710,8964.45189.36%
5 Years7.2019.431.516.362,191,756-0.40-5.56%

ImmunoGen Description

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.


Your Recent History
NASDAQ
IMGN
ImmunoGen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.